Is iShares Nasdaq Biotechnology Index Fund a Buy?

If you lack the time or technical knowledge to invest in biotech, this might be the fund for you and your diversified portfolio.

| More on:

Biotechnology stocks get a lot of attention. It’s easy to be enamored with the curing of disease, and the financial results that could follow the successful introduction of a new treatment can be game-changing.

But, alas, it isn’t as simple as picking a few promising names with lucrative treatment pipelines, sitting back, and watching the positive results roll in. Biotechnology certainly has the potential to be a high-reward investment, but there are extra risks tethered to the industry. Many upstart companies hold a lot of promise, but the path to treatment approval and sales growth is fraught with legal disputes, regulatory and health concerns, and — oh yeah — all the other challenges involved with running a business!

Enter the iShares Nasdaq Biotechnology Index Fund (NASDAQ: IBB). If the ins and outs of the biotech industry are beyond your scope of expertise (like myself), or you lack the time to sift through proposed treatments, trials, and regulatory approval (that’s me, too), this ETF could be worth a look.

What is iShares Biotechnology Index Fund?

iShares Biotechnology Fund is the oldest and largest biotechnology fund around. Fired up all the way back in 2001, a share of this ETF carries an expense ratio of 0.47% a year; so every $1,000 invested gets hit with a $4.70 charge throughout the year, assuming the value of the fund doesn’t change. For that fee, investors get exposure to 219 stocks, passively managed and weighted by the size of the company. In other words, the larger the underlying stock, the larger its percentage of iShares Biotechnology Fund. As of this writing, the fund’s top five and well-known holdings read as such:

Top Five Holdings From iShares Nasdaq Biotechnology Fund  Company Market Cap Portfolio Weighting
Amgen (NASDAQ: AMGN) $121 billion 9.8%
Gilead Sciences (NASDAQ: GILD) $84.0 billion 8.2%
Celgene (NASDAQ: CELG) $68.4 billion 8.2%
Vertex Pharmaceuticals (NASDAQ: VRTX) $44.9 billion 6.4%
Illumina (NASDAQ: ILMN) $39.2 billion 5.4%

Data source: iShares and YCharts.

Stacking up against the competition

iShares is by no means the only game in town for biotech funds, though. For example, there’s the SPDR S&P Biotech ETF (NYSEMKT: XBI) and First Trust NYSE Arca Biotech ETF (NYSEMKT: FBT), also large and well-established funds with a long track record. Both SPDR and First Trust use an equal-weight portfolio — meaning all underlying stocks large and small are periodically rebalanced so that regardless of the companies’ size, they all have the same portfolio weighting. After rebalancing, these weights will change as the stocks increase and decrease in value, but the strategy nevertheless significantly changes what investors should expect from the funds when compared with iShares’ offering.

For one, SPDR S&P Biotech and First Trust NYSE Arca Biotech have fewer holdings — 118 and 30 stocks, respectively. They also are more heavily weighted toward smaller companies. Since smaller outfits have more upward potential if they land a new blockbuster treatment, these funds have outperformed iShares over the long term. The trade-off, though, is that having fewer underlying stocks and concentrating more on smaller companies means potentially more of a roller coaster ride.

Is it a buy?

The biotech industry is one of the more uncorrelated groups of stocks compared with the rest of the stock market. After all, viable new treatments for illness don’t wait for the economy before going to market, nor do they necessarily take off when all’s well in the world of economics. That can be either a good thing or a bad thing. Take this year for example. While the S&P 500 is sporting a 19% gain in 2019 year to date, an initial rally for biotechs has fizzled as of late.

So, is iShares Biotechnology Fund a buy? That depends. This is a volatile place to put money, but if an investor has a long time to wait out the craziness, there’s certainly a lot of growth potential. Of course, the largest biotech ETF should be considered against its peers, and if high growth with an indifference to wild gyrations in value is what you’re after, the SPDR S&P Biotech and First Trust NYSE Arca Biotech funds should be considered as well.

At the end of the day, though, the iShares Nasdaq Biotechnology Index Fund offers exposure to a wide swath of the industry, has an internal expense fee on par with other ETFs vying for your biotech dollars, and has a track record of delivering above-average gains over the long haul. It’s not a bad choice as part of a long-term focused and well-diversified portfolio if you don’t have the time or the expertise to tackle biotechnology.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Nicholas Rossolillo and his clients own shares of Gilead Sciences. The Motley Fool owns shares of and recommends Celgene, Gilead Sciences, and Illumina. The Motley Fool recommends Amgen and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

More on Tech Stocks

Coronavirus written newspaper close up shot to the text.
Tech Stocks

The 2 Best Tech Stocks to Buy Today for Low-Risk Investors

Overvalued tech stocks are undergoing a major correction after inflating on the back of high liquidity from fiscal stimulus packages. …

Read more »

Choose a path
Tech Stocks

Is Ripple Primed for 100% Growth in 2022?

From an investment perspective, most cryptocurrencies seem similar. Almost all of them seem volatile, and while some get more limelight …

Read more »

Tech Stocks

Tech Crash: 2 Tech Stocks Analysts Have Sliced in Half

The TSX has continued to wax and wane over the past week. After a huge fall on Monday, shares started …

Read more »

Hand holding smart phone with online shop concept on screen
Tech Stocks

Shopify Stock Selloff: Could it Turn Around in February?

Shopify (TSX:SHOP)(NYSE:SHOP) continues to be one of the worst-affected stocks amid the ongoing market selloff. After posting its worst weekly …

Read more »

analyze data
Tech Stocks

TFSA Investors: Is the Tech Crash Over?

It’s been a hard time for Tax-Free Savings Account (TFSA) investors already in 2022. Almost immediately after ringing in the …

Read more »

value for money
Tech Stocks

4 Cheap TSX Stocks to Buy Under $50

The recent selloff in equities has led to a sharp pullback in high-quality TSX stocks. Many of these Canadian stocks …

Read more »

edit U-turn
Tech Stocks

2 Canadian Growth Stocks That Could Rebound Nicely From Here

Finding top growth stocks has been a winning strategy over the past decade. Many have posted life-changing returns over a …

Read more »

edit Sale sign, value, discount
Tech Stocks

Tech Stock Crash: Time to Buy 2 Stocks at Bargain Prices

After an incredibly strong year in 2021, the Canadian market is off to a rocky start this year. The S&P/TSX …

Read more »